The research was conducted by Xiaohua Ying and team from Fudan University and published in Infectious Diseases of Poverty. This study investigates the vaccination rates and primary obstacles associated with four non-National Immunization Program (NIP) vaccines in China which reveals disparate coverage rates, with the Hib vaccine leading at 54.9-55.9%. The research underscores the urgency of improving the coverage for these vaccines, reducing regional disparities, and suggests a cautious, gradual approach to their inclusion in the national immunization plan, with special attention to high-risk populations and underdeveloped regions.
Adding new childhood vaccines to China’s National Immunization Program: evidence, benefits, and priorities
The research was conducted by Hai Fang and team from Peking University and published in The Lancet Public Health. The study assessed the impact of introducing four non-National Immunization Program (NIP) vaccines in China, considering both public health benefits and cost-effectiveness. The multicriteria decision analysis suggests that incorporating these vaccines into the NIP could follow the priority order to benefit the Chinese population: PCV13, rotavirus vaccine, Hib vaccine, and varicella vaccine.